CD8A and neoplasm: Tumor-bearing mice treated with pBI-11 or pBI-12 had significantly higher percentages of HPV16 E7-specific CD8+ T cell-mediated immune responses than mice vaccinated with pBI-10.1 (Fig. 5B).